SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming utilities, P2E Telegram games, and weekly contests to reward holders. Discussions highlight a potential token burn event at 2500 watchers, alongside the coin's resilience as a Solana survivor meme coin. Community members emphasize active development and ongoing efforts to engage and reward the "Spare Change Army".

BENQI is a decentralized non-custodial liquidity market protocol, built on Avalanche. The protocol enables users to effortlessly lend, borrow, and earn interest with their digital assets. Depositors providing liquidity to the protocol may earn passive income, while borrowers are able to borrow in an over-collateralized manner.

Benqi Finance

Benqi Finance is trending as community members highlight its potential within the Avalanche network, noting its fully diluted supply and predictions of significant influx of RWAs; the overall sentiment suggests a possible run. Some users point to Forbes coverage and increasing TVL as reasons for optimism, while others focus on tokenomics and compare it to other DeFi projects.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst community disagreement on its potential, with some expressing frustration over its price action relative to Bitcoin's surge and other altcoins. Discussions revolve around potential catalysts, including partnerships and broader market trends, while others dismiss the project as a lost cause, pointing to its ranking decline. The community is split between those who remain optimistic, accumulating more JASMY, and those who are highly critical, predicting further decline.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as investors discuss the company's potential as an AI acquisition target, particularly after recent activity in the data labeling space. Community members are analyzing INOD's recruitment strategies, financial positioning, and technical indicators, interpreting them as signs of a potential takeover or significant new contracts. Bullish sentiment prevails, with focus shifting towards potential short squeezes and price targets.

GME Ethereum

GME Ethereum is trending as the community anticipates a "God Candle" and a tweet from Roaring Kitty, potentially signaling a major surge. Discussions also revolve around JTR Crypto (JTRAMBO) and its recent market cap milestones, with community members emphasizing a "buy and hold" strategy. However, some users are raising concerns about the legitimacy of the project and its affiliation with GameStop.

ARK Investment Management LLC - ARK Genomic Revolution ETF

ARKG is gaining attention as investors discuss potential breakout patterns and compare its performance to other ARK funds, with some expressing frustration over its historical returns. Community members are actively debating entry points and speculating on future catalysts, particularly the impact of AI on genomic advancements. Despite mixed sentiment regarding management, there's anticipation for a potential sector-wide upswing and the impact of future rate cuts.

KULR Technology Group, Inc. engages in developing, manufacturing, and licensing next-generation carbon fiber thermal management technologies for batteries and electronic systems. Its products include cellcheck, safecase, thermal capacitor, fiber thermal interface, thermal runaway shield, internal short circuit, and cathode. The company was founded by Michael Mo and Timothy R. Knowles in December 2015 and is headquartered in Webster, TX.

KULR Technology Group Inc

KULR is trending due to a surge in volume and community discussion around its Thursday's kBMS launch for defense and space. Bullish sentiment is building, with some eyeing a potential short squeeze and upside to the $7 level. The company's Bitcoin holdings and thermal runaway technology are also being discussed as potential drivers.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users promote the coin and its association with cannabis culture. The community emphasizes the coin's cultural significance, steady growth, and resilience. Some users are also speculating about potential upcoming catalysts such as a CMC listing.

Tether (USDT) is a cryptocurrency with a value meant to mirror the value of the U.S. dollar. The idea was to create a stable cryptocurrency that can be used like digital dollars. Coins that serve this purpose of being a stable dollar substitute are called “stable coins.” Tether is the most popular stable coin and even acts as a dollar replacement on many popular exchanges! According to their site, Tether converts cash into digital currency, to anchor or “tether” the value of the coin to the price of national currencies like the US dollar, the Euro, and the Yen. Like other cryptos it uses blockchain. Unlike other cryptos, it is [according to the official Tether site] “100% backed by USD” (USD is held in reserve). The primary use of Tether is that it offers some stability to the otherwise volatile crypto space and offers liquidity to exchanges who can’t deal in dollars and with banks (for example to the sometimes controversial but leading exchange Bitfinex).  The digital coins are issued by a company called Tether Limited that is governed by the laws of the British Virgin Islands, according to the legal part of its website. It is incorporated in Hong Kong. It has emerged that Jan Ludovicus van der Velde is the CEO of cryptocurrency exchange Bitfinex, which has been accused of being involved in the price manipulation of bitcoin, as well as tether. Many people trading on exchanges, including Bitfinex, will use tether to buy other cryptocurrencies like bitcoin. Tether Limited argues that using this method to buy virtual currencies allows users to move fiat in and out of an exchange more quickly and cheaply. Also, exchanges typically have rocky relationships with banks, and using Tether is a way to circumvent that.  USDT is fairly simple to use. Once on exchanges like Poloniex or Bittrex, it can be used to purchase Bitcoin and other cryptocurrencies. It can be easily transferred from an exchange to any Omni Layer enabled wallet. Tether has no transaction fees, although external wallets and exchanges may charge one. In order to convert USDT to USD and vise versa through the Tether.to Platform, users must pay a small fee. Buying and selling Tether for Bitcoin can be done through a variety of exchanges like the ones mentioned previously or through the Tether.to platform, which also allows the conversion between USD to and from your bank account.

Tether

USDT is trending as community members discuss its relationship with Rumble, including Tether's stake in the company and the upcoming integration of USDT payments in the Rumble Wallet. There is also discussion around Tether's role in the broader crypto market, including minting activities and its dominance among stablecoins. The potential impact of new regulations and competition from other stablecoins are also being considered.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors celebrate the stock's recent gains, with many long-term holders expressing excitement about breaking past the $40 mark and some anticipating a Nasdaq relisting. Community members are also discussing the company's expansion in China and the U.S., viewing it as a potential challenger to Starbucks, especially as Luckin innovates with new products and offers competitive pricing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of treatment.At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading.According to the Kansas-based biotech, children who took CTx-1301 at doses of 18.75 mg, 25 mg, and 37.5 mg experienced significant reductions in their ADHD-RS-5 scores.Dr. Raul Silva, chief science officer at Cingulate, revealed the possibility of CTx-1301 becoming a primary treatment option for ADHD after demonstrating effect sizes between 0.737 and 1.185, which surpass the industry standard of 0.73 for long-duration stimulants.CEO Shane Schaffer identified the findings as a “significant value inflection point” while confirming that the company plans to file a New Drug Application (NDA) this summer.CTx-1301 uses Cingulate’s Precision Timed Release platform to provide a single daily dose, which begins working in the morning and maintains effectiveness throughout the day.After receiving FDA approval, the company plans to offer eight different dosage strengths to address the pediatric and adult ADHD markets.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,700% surge in 24-hour message volume.One user highlighted the forthcoming FDA submission as a key milestone and suggested that the recent decline in share price may offer a buying opportunity.&nbsp;<stembedurl>https://stocktwits.com/Duke1979/message/615297512</stembedurl>Another user was more cautious, noting that the effect size observed in the pediatric trial appeared lower than earlier projections. However, they acknowledged that sustained efficacy throughout the day could remain a key differentiator.<stembedurl>https://stocktwits.com/TheSterl/message/615215732</stembedurl>The stock has declined 29% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

Phase 3 data showed the company’s ADHD drug, CTx-1301, significantly improved symptoms in children within five weeks. The company plans to file for FDA approval this summer.

Equity

Cingulate Inc.'s shares generated heightened retail chatter on Wednesday after receiving the FDA's pre-New Drug Application (NDA) meeting minutes for its primary asset CTx-1301 that targets ADHD with a daily stimulant treatment.Cingulate shares rose 8.7% to close at $4.25 on Tuesday but slipped 4.2% to $4.07 in after-hours trading.Following a pre-NDA meeting on April 2, the company confirmed that it will submit an NDA for CTx-1301 in the summer of 2025 based on the FDA’s feedback.&nbsp;The formulation CTx-1301 contains dexmethylphenidate and employs Cingulate’s Precision Timed Release technology to provide three doses during specific times of the day.&nbsp;The technology aims to overcome the problem of reduced effectiveness in existing stimulant treatments during the afternoon hours.The FDA minutes confirmed that the existing nonclinical safety data sufficiently support the NDA submission.The agency entered into a post-approval agreement with Cingulate to gather stability data for six intermediate dose strengths, spanning from 12.5 mg to 43.75 mg.The regulatory body recognized a scientific connection to Focalin XR, which permitted Cingulate to benefit from existing data on drug effectiveness and safety.&nbsp;The agency found the company’s integrated safety and efficacy summary approaches reasonable.One user said the stock could reach $6, citing a sharp spike to $5.16 as a signal of potential upward momentum.&nbsp;On Stocktwits, retail sentiment was ‘bullish’ amid a 1,600% surge in 24-hour message volume.<stembedurl>https://stocktwits.com/doublenickels55/message/614579894</stembedurl>Another user highlighted the absence of negative news and reaffirmed confidence in the NDA timeline, noting the company remains on track for a summer submission.<stembedurl>https://stocktwits.com/fullobullz/message/614577626</stembedurl>The stock has declined 16.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug

CTx-1301 employs its Precision Timed Release system to administer three doses of dexmethylphenidate throughout the day for managing ADHD symptoms.

What's Going On With Cingulate Shares Recently?

Cingulate Inc. (NASDAQ: CING) shares are soaring Friday. the stock is trading with a session volume of 3.297 million shares, approaching its 100-day average volume of 3.654 million shares.
read more...

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301...

<a href="https://stocktwits.com/symbol/CING">Cingulate Inc</a>. (CING) shares skyrocketed over 85% in pre-market trading on Friday, becoming the top trending stock on Stocktwits. The surge comes after the stock rallied nearly 160% on Thursday, triggered by the company's announcement of a European patent for its ADHD drug candidate, CTx-1301.This patent expands Cingulate's intellectual property protection to include up to 30 European countries, adding to its existing patents in Australia, Canada, and Israel. The company is also pursuing patents in Hong Kong, South Korea, and the United States.ADHD is a significant global health issue, affecting millions worldwide. Cingulate's focus on developing treatments for ADHD aligns with its broader strategy of utilizing its proprietary PTR technology for other therapeutic areas, such as anxiety disorders.The patent news has injected a much-needed dose of optimism into the stock, which has lost over 94% of its value this year due to several headwinds.The company reported disappointing Q2 earnings and has been grappling with financial challenges, including a significant cash burn and a history of top executive departures.Cingulate has a cash balance of just $0.4 million as of June 30, 2024. To address this, the company raised $1.6 million in July through warrant inducement and plans to seek additional funding.A regulatory filing last year warned of potential bankruptcy if financial issues persisted.<stembedurl>https://stocktwits.com/SelectiveTrader/message/583139933</stembedurl>Despite these challenges, the European patent news has reignited interest in Cingulate. However, it remains to be seen if this momentum can be sustained and if the company can successfully navigate its financial hurdles to capitalize on its drug development pipeline. &nbsp;

ADHD is a significant global health issue, affecting millions worldwide. Image via Vecteezy

Cingulate Stock Is Hottest Talk Of Retail Street After Europe Patent For ADHD Drug Candidate

Retail investors, buoyed by the news, are actively discussing the stock on Stocktwits. However, some remain cautious due to the company's troubled history and ongoing financial challenges.

Top 5 Trending Stocks Of The Day: Amazon, AST Spacemobile, Cingulate, Applied Materials, And Tesla

On Thursday, major U.S. indices closed higher, with the Dow Jones Industrial Average increasing by 1.4% to 40,563.06.
read more...

What's Going On With Cingulate Shares Today?

Cingulate shares are surging, trading over 173% higher today. Here's what's driving the movement.
read more...

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE...

Cingulate reports Q4 EPS net loss $6.9M

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cingulate CEO talks about the pharmaceutical company's road ahead after tough 2023

CEO Shane Schaffer says a ripple from the collapse of Silicon Valley Bank set in motion a tough financial year for his Kansas City, Kansas, company...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$4.18
Prev Close	$4.06
Open	$4.04
Dividend Yield	0.00%
50-Day Moving Average	$4.19
Beta	0.36
Avg. Volume	151,955.95
PE Ratio	-0.70

52-Week High	$6.01
52-Week Low	$3.02
Market Capitalization	$21.97M
EPS (Annual)	-$10.20
Price to Book	3.60
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CING News

CING Cingulate Inc